The english version of the website of the School of Medicine is under development

Δημοσίευση

Epileptic seizures after octreotide administration in a 6.5-year-old female with ALL and L-asparaginase associated pancreatitis: a possible drug interaction.

TitleEpileptic seizures after octreotide administration in a 6.5-year-old female with ALL and L-asparaginase associated pancreatitis: a possible drug interaction.
Publication TypeJournal Article
Year of Publication2011
AuthorsHatzipantelis, E., Pana Z. D., Pavlou E., Balakou E., Tsotoulidou V., Papageorgiou T., Tragiannidis A., & Athanassiadou F.
JournalKlin Padiatr
Volume223
Issue6
Pagination360-3
Date Published2011 Nov
ISSN1439-3824
KeywordsAcute Disease, Anticonvulsants, Asparaginase, Child, Diagnosis, Differential, Drug Interactions, Electroencephalography, Epilepsy, Female, Humans, Octreotide, Pancreatitis, Piracetam, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Abstract

INTRODUCTION: Octreotide is a synthetic somatostatin analogue which has been suggested for use in the management of acute pancreatitis, though its safety and effectiveness in the pediatric setting has not been extensively studied.CASE REPORT: we present a rare case of a 6.5-year-old female with acute lymphoblastic leukemia (ALL) and L-asparaginase (L-asp) induced pancreatitis, who developed epileptic seizures, possibly associated with octreotide administration. Her imaging and laboratory findings ruled out a leukemic involvement or infection of CNS. The EEG revealed repetitive sharp waves maximal on the frontal and temporal areas of the right hemisphere. The child was treated with diazepam and she continued with systemic anticonvulsant treatment with levetiracetam. After 2 weeks of conservative treatment, pancreatitis resolved and she continued her chemotherapy protocol. Levetiracetam treatment lasted 8 months. 7 months after the first episode, EEG was reported as normal, and the child completed the chemotherapy protocol without any further severe complications.CONCLUSIONS: Larger and well designed studies are needed to warrant the safety of octreotide in pediatric population.

DOI10.1055/s-0031-1287827
Alternate JournalKlin Padiatr
PubMed ID22052632

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.